Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Increased ventral striatal monoaminergic innervation in Tourette syndrome

Increased ventral striatal monoaminergic innervation in Tourette syndrome Increased ventral striatal monoaminergic innervation in Tourette syndrome R.L. Albin, MD; R.A. Koeppe, PhD; N.I. Bohnen, MD, PhD; T.E. Nichols, PhD; P. Meyer, MD; K. Wernette, MSN; S. Minoshima, MD, PhD; M.R. Kilbourn, PhD; and K.A. Frey, MD, PhD Abstract—Background: Excessive striatal dopaminergic innervation is suggested to underlie Tourette syndrome (TS). Prior imaging and postmortem studies yield conflicting data. Methods: The authors used PET with the type 2 vesicular monoamine transporter ligand [ C]dihydrotetrabenazine (DTBZ) to quantify striatal monoaminergic innervation in patients with TS (n  19) and control subjects (n  27). Compartmental modeling was used to determine blood to brain ligand transport (K ) and tissue to plasma distribution volume (a measure of ligand binding) during continuous infusion of DTBZ. TS data were compared with control data using predefined regions of interest and on a voxel by voxel basis. Results: There were no significant differences in ligand binding or ligand transport between patients with TS and control subjects in the dorsal striatum. With voxel by voxel analysis, there was increased DTBZ binding in the right ventral striatum. Conclusions: Previously reported differences between patients with TS and control subjects in dorsal striatal dopamine terminal markers may reflect medication-induced http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Neurology Wolters Kluwer Health

Increased ventral striatal monoaminergic innervation in Tourette syndrome

Frey, K.A.
Neurology , Volume 61 (3) – Aug 1, 2003
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/increased-ventral-striatal-monoaminergic-innervation-in-tourette-r07uWjGR1p

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0028-3878
eISSN
1526-632X
DOI
10.1212/01.WNL.0000076181.39162.FC
Publisher site
See Article on Publisher Site

Abstract

Increased ventral striatal monoaminergic innervation in Tourette syndrome R.L. Albin, MD; R.A. Koeppe, PhD; N.I. Bohnen, MD, PhD; T.E. Nichols, PhD; P. Meyer, MD; K. Wernette, MSN; S. Minoshima, MD, PhD; M.R. Kilbourn, PhD; and K.A. Frey, MD, PhD Abstract—Background: Excessive striatal dopaminergic innervation is suggested to underlie Tourette syndrome (TS). Prior imaging and postmortem studies yield conflicting data. Methods: The authors used PET with the type 2 vesicular monoamine transporter ligand [ C]dihydrotetrabenazine (DTBZ) to quantify striatal monoaminergic innervation in patients with TS (n  19) and control subjects (n  27). Compartmental modeling was used to determine blood to brain ligand transport (K ) and tissue to plasma distribution volume (a measure of ligand binding) during continuous infusion of DTBZ. TS data were compared with control data using predefined regions of interest and on a voxel by voxel basis. Results: There were no significant differences in ligand binding or ligand transport between patients with TS and control subjects in the dorsal striatum. With voxel by voxel analysis, there was increased DTBZ binding in the right ventral striatum. Conclusions: Previously reported differences between patients with TS and control subjects in dorsal striatal dopamine terminal markers may reflect medication-induced

Journal

Neurology – Wolters Kluwer Health

Published: Aug 1, 2003

There are no references for this article.